OBJECTIVE: Barcelona @entity96 (BCLC) stage @entity157 ( @entity157 ) is a heterogeneous disease group. Transarterial chemoembolization (TACE) is indicated for BCLC stage B @entity157 , while @entity2857 is indicated for BCLC stage C @entity157 . This study aimed to evaluate the efficacy of TACE+ @entity2857 compared with TACE monotherapy in the treatment of BCLC stage B @entity157 . MATERIALS: @entity1 with BCLC stage B unresectable @entity157 . METHODS: This was a retrospective study in @entity1 with BCLC stage B @entity157 who received TACE (n  =  144) or TACE+ @entity2857 (n  =  46) between January 2008 and January 2014. @entity1 -Pugh classification, history of @entity99 or @entity82 , nodule number, @entity5 vascularity, ECOG performance status, adverse events, and survival were evaluated. @entity1 were matched 1  :  1 using the propensity score approach. RESULTS: Median overall survival (OS) was 18.0 months in the TACE+ @entity2857 group compared with 10.0 months for TACE (p  =  0.002). In matched @entity1 , multivariate analysis showed that the use of TACE+ @entity2857 (HR  =  0.351, 95%CI: 0.215-0.574, p  <  0.001) and multiple-diffuse nodules (HR  =  0.497, 95% CI: 0.293  -  0.884, p  =  0.010) were independently associated with a better prognosis. Subgroup analysis showed survival benefits for @entity1 with @entity1 -Pugh A classification (p  =  0.001), @entity82 (p  =  0.001), @entity1956 (p  <  0.001), @entity75 (p  =  0.001), and both single/multiple nodules p  =  0.001). Cumulative rates of adverse events were similar between the two groups (p  =  0.155), but @entity8566 (58.7% vs. 12.5%, p  <  0.001) and @entity294 (60.9% vs. 40.3%, p  =  0.02) were more frequent in the TACE+ @entity2857 group. CONCLUSIONS: The combination of TACE+ @entity2857 might improve the OS of @entity1 with BCLC stage B @entity157 . These results also suggest that some subsets of @entity1 could benefit more from the TACE+ @entity2857 combination.

Overall survival in response to @entity2857 with  transarterial chemoembolization for BCLC  stage XXXX : propensity  score analysis   .

@entity1 :: ('9606', 'Species') :: ['Child', 'Patients', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity1956 :: ('MESH:D006509', 'Disease') :: ['hepatitis B'] @entity96 :: ('MESH:D008113', 'Disease') :: ['clinic liver cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity75 :: ('MESH:D001927', 'Disease') :: ['hypovascular lesion'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'B hepatocellular carcinoma'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatitis']
@entity157 :: (MESH:D006528,Disease) :: ['B hepatocellular carcinoma']
